Imaging News

CV risk factors, particularly hypertension, were linked to impaired brain metabolism tied to cognitive decline and were identifiable at midlife among asymptomatic patients with subclinical atherosclerosis, researchers reported.

The editorial team of Circulation: Cardiovascular Quality and Outcomes issued a statement urging scientific journals to address racial/ethnic disparities prevalent in health science research, particularly CV trials.

Elevated non-HDL was associated with coronary artery calcification in mid-adulthood, with the strongest association among those with high non-HDL in adolescence, researchers reported in JAMA Cardiology.

The first Friday each February marks National Wear Red Day, to raise awareness about heart disease.

Global longitudinal strain may be an effective tool for risk stratification of patients with chronic HF, according to data from the MyoVasc study published in JAMA Cardiology.

Women who developed first-time gestational diabetes and returned to normal blood glucose levels after pregnancy may experience a twofold increased risk for developing atherosclerotic CVD, according to new data from the CARDIA study.

The first technique for coronary artery calcium scoring was published in 1990. Given the lack of data at the time on CAC and coronary atherosclerosis burden, the algorithm was remarkable yet unactionable.

Older patients and those with chronic kidney disease who have abdominal aortic calcification are at elevated risk for future CV events and poorer prognosis, according to results published in the Journal of the American Heart Association.

Among patients with asymptomatic aortic valve stenosis, elevated acceleration time/ejection time ratio was associated with increased CV mortality and morbidity, according to data published in Circulation: Cardiovascular Imaging.

Empagliflozin, an SGLT2 inhibitor, improved left ventricular function and quality of life in patients with HF with reduced ejection fraction and without diabetes, according to findings from the EMPA-TROPISM trial.